Company news

Nektar Therapeutics news in 2026

Nektar Therapeutics's news releases, calls and decks from 2026, newest first.

View company

Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets

October 27, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 23, 2026

/UPDATE -- Nektar Therapeutics/

October 1, 2026

New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

October 1, 2026

New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis

September 30, 2026

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

September 28, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)

August 31, 2026

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

August 25, 2026

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

August 13, 2026

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

July 28, 2026

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

July 21, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 26, 2026

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

May 27, 2026

Nektar Therapeutics Reports First Quarter 2026 Financial Results

May 7, 2026

Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets

April 28, 2026

Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

April 23, 2026

Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering

April 20, 2026

52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin

April 20, 2026

Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026

April 19, 2026

Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

March 27, 2026

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

March 19, 2026

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

March 11, 2026

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

February 25, 2026

Nektar Therapeutics to Participate in Two Investor Conferences in March

February 23, 2026

Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis

February 16, 2026

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

February 13, 2026

Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering

February 11, 2026

New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

February 10, 2026

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

February 9, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 30, 2026

Calls in 2026

Decks in 2026